Table 3 SE and anticalpastatin peptide positivity.

	Peptide 28 n (%)
RA patients	126 (44)
SE+/SE+	49 (59)
SE+/SE–	51 (31)
HLA‐DRB1*
0404/SE–	16 (50)
0101/SE–	18 (33)
0401/SE–	17 (12)
SE–	26 (38)
Controls	82 (14)

n, number of patients.